CLOS
DNA icon

Compagnie Lombard Odier SCmA’s Ginkgo Bioworks DNA Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-350
Closed -$43K – 672
2022
Q3 		$43K Buy
+350
New +$41.7K ﹤0.01% 472

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Compagnie Lombard Odier SCmA's DNA Position: Q4 2022 in Review

Compagnie Lombard Odier SCmA sold out of Ginkgo Bioworks (DNA) in Q4 2022, closing a stake of 350 shares — an estimated $43K sold.

Compagnie Lombard Odier SCmA first reported a position in DNA in Q3 2022 and held it in 1 quarter. The position peaked at $43K in Q3 2022. 320 funds tracked by Wall St. Rank hold DNA as of Q4 2022.

  • Compagnie Lombard Odier SCmA reported no remaining Ginkgo Bioworks position as of Q4 2022 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 350 Ginkgo Bioworks shares in Q4 2022, an estimated $43K.
  • Compagnie Lombard Odier SCmA first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's Ginkgo Bioworks position peaked at $43K in Q3 2022.
  • 320 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2022.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2022, filed 13 Feb 2023.